AbCellera Biologics (ABCL) EPS (Weighted Average and Diluted) (2020 - 2023)
AbCellera Biologics (ABCL) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.17 as the latest value for Q4 2023.
- For the quarter ending Q4 2023, EPS (Weighted Average and Diluted) fell 70.0% year-over-year to -$0.17, compared with a TTM value of -$0.51 through Dec 2023, down 202.0%, and an annual FY2024 reading of -$0.55, down 7.84% over the prior year.
- EPS (Weighted Average and Diluted) was -$0.17 for Q4 2023 at AbCellera Biologics, down from -$0.09 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.54 in Q1 2022 and bottomed at -$0.17 in Q4 2023.
- Average EPS (Weighted Average and Diluted) over 4 years is $0.06, with a median of -$0.01 recorded in 2020.
- Peak annual rise in EPS (Weighted Average and Diluted) hit 3800.0% in 2021, while the deepest fall reached 700.0% in 2021.
- Year by year, EPS (Weighted Average and Diluted) stood at $0.44 in 2020, then tumbled by 54.55% to $0.2 in 2021, then crashed by 150.0% to -$0.1 in 2022, then crashed by 70.0% to -$0.17 in 2023.
- Business Quant data shows EPS (Weighted Average and Diluted) for ABCL at -$0.17 in Q4 2023, -$0.09 in Q3 2023, and -$0.11 in Q2 2023.